GlassScriptPhysician profile
Krishna C Vedala
NPI 1366939563
$1,677.17
in general payments reported to CMS, 2019-2025
19 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.43 · 2023: $503 · 2024: $487 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.87 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $217.80 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $207.46 | 2023-2025 | Ubrelvy |
| Novo Nordisk INC | $175.38 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.50 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $104.46 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $95.26 | 2023-2024 | Veozah |
| Rhythm Pharmaceuticals, INC. | $93.12 | 2025 | Imcivree |
| Glaxosmithkline, LLC. | $90.20 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Shield Therapeutics INC | $81.92 | 2025 | |
| Lilly USA, LLC | $69.52 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $67.98 | 2023-2025 | Cologuard Collection Kit |
| Globus Medical, INC. | $25.86 | 2025 | Senza |
| Antares Pharma, INC. | $22.23 | 2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $19.34 | 2023 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $17.70 | 2023 | |
| Pfizer INC. | $17.09 | 2025 | |
| Dexcom, INC. | $15.23 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $14.25 | 2023 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Vedala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.